Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
A phase 3 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., active and no longer recruiting.
Overview
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer is a phase 3 interventional study registered as NCT01436968 by Candel Therapeutics, Inc., with 711 participants planned, started 2011-09 and due to reach its primary completion in 2024-08. Interventions recorded: Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialRandomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
- TrialA Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
- TrialAglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
- TrialCAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC